Aussie Institute Urges Coverage Of Osteoporosis Drugs For Breast Cancer
This article was originally published in PharmAsia News
Executive Summary
Health experts in Australia are calling on the government to cover the use of osteoporosis drugs for women with a high risk of breast cancer. The New South Wales Cancer Institute cited international trials that have demonstrated tamoxifen and raloxifene are effective in preventing breast cancer. The head of the institute said Australia's Pharmaceutical Benefits Scheme should place both drugs on its formulary even though they would cost the government $187.7 million. He said the expenditure would be cost-effective in the long run. (Click here for more